Multidisciplinary Approach to Patient with Malignant Melanoma

Author(s): Giuseppina Della Vittoria Scarpati , Celeste Fusciello , Francesco Sabbatino , Soldano Ferrone , Francesco Caponigro , Francesco Perri , Chiara Carlomagno , Stefano Pepe .

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 13 , Issue 6 , 2013

Become EABM
Become Reviewer

Abstract:

The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2].

A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4].

Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5].

To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

Keywords: Melanoma, immunotherapy, B-RAF inibithors, chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 6
Year: 2013
Page: [887 - 900]
Pages: 14
DOI: 10.2174/18715206113139990079
Price: $58

Article Metrics

PDF: 13